Join to view full profile
10 Center Drive10/Room 12n226Bethesda, MD 20892
Dr. Karzai is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Fatima Karzai is an oncology specialist based in Bethesda, MD, who graduated from George Washington University School of Medicine and Health Sciences. Her expertise includes prostate cancer, medical oncology, AI, and tumor imaging. She has authored several publications, including notable research on treatment-resistant prostate cancer and colorectal cancer trials. Dr. Karzai has been actively involved in clinical trials, serving as a principal investigator and contact for projects focusing on genomics, high-risk prostate cancer imaging, and clinical trial design in prostate cancer.
Education & Training
George Washington University School of Medicine and Health SciencesClass of 2005
Certifications & Licensure
MD State Medical License 2009 - 2028
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Roles: Contact, Principal Investigator
- Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Roles: Principal Investigator, Contact
- Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsTherapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging.Melissa L Abel, Adam Sharp, Edwin M Posadas, Fatima Karzai, Frank I Lin
Nature Reviews. Urology. 2026-08-01 - Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resi...Jason Mark Redman, Ravi A Madan, Renee N Donahue, Nicole J Toney, Fatima Karzai
Journal for Immunotherapy of Cancer. 2026-07-24 - PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.Ginette Santiago-Sanchez, Francesca Rosato, Kellsye P Fabian, Michelle R Padget, Jung-Min Lee
Journal for Immunotherapy of Cancer. 2026-07-01
Journal Articles
- Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy MeetingThomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Press Mentions
Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended Treatments, Study FindsFebruary 18th, 2025
Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
